Skip to Content
Shadow

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Agile Therapeutics Reports Second Quarter 2016 Financial Results
Twirla® Clinical Trial Expected to Complete in Fourth Quarter 2016 and Resubmission Planned for First Half 2017; Cash Expected to Fund Operations Through the End of 2017...
Toggle Summary Agile Therapeutics Reports Second Quarter 2017 Financial Results
Cash Expected to Fund Operations into Q2 2018 FDA Assigns Prescription Drug User Fee Act (PDUFA)  Goal Date of December 26, 2017 PRINCETON, N.J., July 28, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company today reported financial results for the three and...
Toggle Summary Agile Therapeutics Reports Second Quarter 2018 Financial Results
Cash Expected to Enable Company to Fund Operations into Second Quarter 2019 PRINCETON, N.J. , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three and six months ended June 30, 2018 and provided a...
Toggle Summary Agile Therapeutics Reports Second Quarter 2019 Financial Results
FDA Assigned PDUFA (Prescription Drug User Fee Act) Goal Date is November 16, 2019 Cash Expected to Enable Company to Fund Operations through the End of 2019 PRINCETON, N.J. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported...
Toggle Summary Agile Therapeutics Reports Second Quarter 2020 Financial Results
Twirla ® on Track for Commercial Launch in Fourth Quarter 2020 $87.2 Million in Cash and Cash Equivalents as of June 30, 2020   Management to Host Conference Call at 4:30 PM ET PRINCETON, N.J. , Aug. 11, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc....
Toggle Summary Agile Therapeutics Reports Second Quarter 2021 Financial Results
Total Prescriptions (TRx) Grew 171% in Second Quarter Prescribers, New Prescriptions and Refill Rates Continue to Grow in Second Quarter Company Continues to Progress on Expanding Access to Twirla Management to Host Conference Call Today, Monday, July 26, 2021 at 4:30 p.m....
Toggle Summary Agile Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Second Consecutive Quarter of Increase in Twirla Demand and Decrease in Company Operating Expenses Cash on Hand Expected to Fund Operations Through 2022 Company Announces Twirla ® Product Supply Agreement with Nurx Management to Host Conference Call Today, Thursday, August 11, 2022 at 4:30 p.m....
Toggle Summary Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Twirla Delivers Second Quarter 2023 Net Revenue of $5.5 Million, a 44% Increase from First Quarter 2023 Twirla Demand and Factory Sales Up 24% and 42% Respectively in Second Quarter 2023 Compared to First Quarter 2023 Gross Margin Grows to 58% in Second Quarter 2023 from 47% in First Quarter 2023...
Toggle Summary Agile Therapeutics Reports Second Quarter Financial Results
Continues to Progress Clinical Trial; Patents for Proprietary Platform to Develop New Women's Contraceptive Products Allowed...
Toggle Summary Agile Therapeutics Reports Third Quarter 2014 Financial Results
Company Continues to Progress Clinical Trial Site Activation and Subject Enrollment...
Shadow